ARTICLE | Regulation
Approval marks the start of a new disease-modifying treatment paradigm for the rare disease and related indications
By Lauren Martz, Executive Director, Biopharma Intelligence
March 26, 2024 11:38 PM UTC
Updated on Mar 27, 2024 at 10:08 PM UTC
Editor’s note: This article has been updated to reflect the therapy’s price and its method of delivery


With the approval of first-in-class Winrevair sotatercept from Merck, pulmonary arterial hypertension patients gain a therapeutic mechanism that targets the underlying disease pathology — abnormal signaling in the pulmonary artery walls — marking the start of a disease-modifying treatment paradigm for PAH and related indications.
Winrevair, which Merck & Co. Inc. (NYSE:MRK) gained through its $11.5 billion acquisition of Acceleron Pharma Inc. in 2021, was approved to treat PAH, a population that Merck told BioCentury represents about 40,000 patients in the U.S. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651876/merck-s-sotatercept-approval-brings-vascular-remodeling-to-pah